Our viral vaccine capabilitiess include generation, production, purification and analysis of DNA and RNA viruses manufactured on mammalian cell lines.
Our contribution to Global Health
In pursuit of increasing global vaccination coverage, we are committed to develop technologies that substantially lower the cost of vaccine manufacturing. Hereto, we develop highly intensified production process for viral vaccines, HIP-Vax, to reduce cost of product by decreasing CAPEX and cost of goods. Furthermore, we have developed SCOUT® technology to reduce development timelines and time to market. As it is known that costs of capital (53%) and cost of failure (40%) are the biggest cost attributes to a vaccine price paid by consumers, our platforms substantially aid global health initiatives to reach their goals.
Viral vaccines track record
We have extensive experience in manufacturing a wide range of viruses including polio, measles, rubella, influenza and rotavirus. We are proud to have delivered vaccine products for phase-I and phase-II clinical studies in both the EU and US markets. Our experience in the field, anchored in production, purification, and testing protocols, has resulted in a successful track record in delivering vaccine products. For example, in a collaboration with PATH, we have manufactured GMP virus stocks of several novel oral polio vaccine strains. In addition, in collaboration with Prof. Marcellus Ubbink (Leiden University, Netherlands) we are developing a very promising new class of vaccines: self-adjuvating, thermostable influenza vaccines.
Viral vaccines technologies
Under the HIP-Vax® brand, we market our process development services and know-how which enables fast and low-cost vaccine manufacturing using bioprocess intensification technologies.
The SATIRN® technology delivers a platform to manufacture potent, self-adjuvating, thermostable, membrane protein-based vaccines.